COMMUNIQUÉS West-GlobeNewswire

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
19/08/2025
Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 MAESTRO-NASH trial [...]
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
19/08/2025
Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tract Profound mast cell depletion did not result in improved clinical outcomes providing direct [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 15, 2025 it granted stock options to purchase an aggregate of 105,169 shares of [...]
Ligand to Participate in September Investor Conferences
19/08/2025
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in [...]
Arcutis to Present at Upcoming Investor Conferences
19/08/2025
WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
NMDP Announces Nationwide Celebration and Fundraiser to Help Patients in Need of Life-Saving Cell Therapy
19/08/2025
NMDP Unite will be held simultaneously on Sept. 20—World Marrow Donor Day—in Atlanta, Houston, New York, Minneapolis and Seattle MINNEAPOLIS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- NMDP℠ (formerly Be The Match ® ), a global [...]
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
19/08/2025
Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ), a clinical-stage [...]
Epione Beverly Hills Releases Landmark Study Led by Dr. Simon Ourian Confirming Long-Term Effectiveness of Non-Surgical Under-Eye Dark Circle Treatment
19/08/2025
Beverly Hills, CA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Epione Beverly Hills , a leader in non-invasive aesthetic treatments, announced today the results of a landmark four-year retrospective study evaluating its [...]
MedX Holdings, Inc. (OTC: MEDH) Med X Holdings Q2 2025 Investor Update: We’re at an Inflection Point
19/08/2025
Sales up; on track for ~$1.5M FY25 revenue. Las Vegas lounge approaching approvals. Leaf-trak POS rolling out Q3. Pipeline building in Florida and California. Austin, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- FOR [...]
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
19/08/2025
Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024. Tevogen maximizes capital efficiency, maintains access to financing to [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2025
19/08/2025
Aggregated presentation by day and by market Statement of transactions in own shares from August 11th to August 15th 2025 Name of the issuer Identity code of the issuer (Legal Entity Identifier) Day of the transaction [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 33 - 2025
19/08/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 11 août au 15 août 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension
19/08/2025
The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway. Endothelin is upregulated in hypertension and is a fundamental mediator in [...]
Life Backup Plan to Be Featured on Business Today with Bill and Giuliana Rancic
19/08/2025
Appearance to Air on Fox Business Network and Bloomberg International Aliso Viejo, CA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Life Backup Plan , the Interoperable Lifecare Platform redefining digital health and safety, is [...]
24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
19/08/2025
LIXTE Biotechnology’s LB-100 Featured in Nature Reviews Cancer Editorial: A Game-Changer in Cancer Therapy Resistance DENVER, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to [...]
Conclusion d’un partenariat entre Affidea et Skin Analytics en vue d’améliorer l’aide au dépistage du cancer de la peau en Europe au moyen d’une technologie IA
19/08/2025
LA HAYE, Pays-Bas, 19 août 2025 (GLOBE NEWSWIRE) -- Affidea , l’un des principaux prestataires paneuropéens de polycliniques de proximité, de diagnostics avancés et de soins pluridisciplinaires, notamment en oncologie, [...]
First Lady Anna Stein, NCDHHS, Morse Clinics Celebrate First Mobile OTP Unit in North Carolina
19/08/2025
Raleigh, NC, Aug. 19, 2025 (GLOBE NEWSWIRE) -- North Carolina on Tuesday took an innovative step in efforts to reduce opioid use and related deaths with the launch of the state’s first Mobile Opioid Treatment Program. [...]
Remedy's Nutrition Launches Premium Modified Citrus Pectin Supplement to Support Cellular Health and Natural Cleansing
19/08/2025
High-Quality Modified Citrus Pectin (MCP) Supplement Offers Enhanced Bioavailability and Purity for Health-Conscious Consumers KEY LARGO, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Remedy's Nutrition, a trusted dietary [...]
Coloplast A/S - Interim Financial Report, 9M 2024/25
19/08/2025
Coloplast A/S - Interim Financial Report, 9M 2024/25 2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin 1 of 28% in Q3. Reported [...]

Pages